Do you assess the cardiovascular risk of patients before starting antigen deprivation therapy for prostate cancer?
0
votes
Yes, in all patients, and I actively monitor their cardiovascular health during treatment
Yes, at baseline, but I do not monitor their cardiovascular health during treatment except if signs or symptoms develop
Only in patients with additional risk factors, but not in all patients
Not usually, but I monitor their cardiovascular health during treatment
Not as a routine procedure